Scheerer, Markus F.

Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes

Agarwal, R., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Mottl, A. K., Rosenstock, J., Rossing, P., Vaduganathan, M., Brinker, M., et al. (2025) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 319

Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials

Groop, P.-H., Dandona, P., Phillip, M., Gillard, P., Edelman, S., Jendle, J., Xu, J., Scheerer, M. F., Thoren, F., Iqbal, N., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 79

Metformin Effect on Nontargeted Metabolite Profiles in Patients With Type 2 Diabetes and in Multiple Murine Tissues

Adam, J., Brandmaier, S., Leonhardt, J., Scheerer, M. F., Mohney, R. P., Xu, T., Bi, J., Rotter, M., Troll, M., Chi, S., et al. (2016) · Diabetes

Metabolism, Diabetes, and CancerMetabolomics and Mass Spectrometry Studies

Cited by 68

Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial

Heerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Ji, L., Mathieu, C., Groop, P.-H., Pratley, R. E., Rosas, S. E., Rossing, P., et al. (2023) · Diabetes Research and Clinical Practice

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 63

Machine Learning Approaches Reveal Metabolic Signatures of Incident Chronic Kidney Disease in Individuals With Prediabetes and Type 2 Diabetes

Huang, J., Huth, C., Covic, M., Troll, M., Adam, J., Zukunft, S., Prehn, C., Wang, L., Nano, J., Scheerer, M. F., et al. (2020) · Diabetes

Chronic Kidney Disease and DiabetesMetabolomics and Mass Spectrometry Studies

Cited by 60